



**Department of Health**  
Heidi Hedberg, Commissioner  
Robert Lawrence, MD, MA, CMO

3601 C Street, Suite 540  
Anchorage, Alaska 99503

**Division of Public Health**  
Lindsey Kato, MPH, Director

<https://health.alaska.gov/dph/Epi>  
24 Hour Emergency (800) 478-0084  
Local (907) 269-8000

**Editors:**  
Joe McLaughlin, MD, MPH  
Louisa Castrodale, DVM, MPH

**Bulletin No. 7**  
September 10, 2024

## Influenza Vaccines Available During the 2024–25 Season

### Vaccines Available

Influenza vaccine options available in the United States this season include Afluria®, Fluarix®, FluLaval®, Fluzone®, Flucelvax®, Fluzone High-Dose®, Fluad®, Flublok®, and FluMist®.<sup>1</sup> The Alaska Immunization Program will supply 6 trivalent influenza vaccines this season (Table). Recommendations and administration information is published in a separate *Bulletin*.<sup>2</sup>

### 2024–25 Influenza Vaccine Composition<sup>1</sup>

For the 2024–25 influenza season, the U.S. Food and Drug Administration (FDA) recommended that the vaccine composition no longer include influenza B/Yamagata, as there has been no detection of this virus since March 2020.

Egg-based influenza vaccines contain hemagglutinin (HA) derived from:

- influenza A/Victoria/4897/2022 (H1N1) pdm09-like virus
- influenza A/Thailand/8/2022 (H3N2)-like virus
- influenza B/Austria/1359417/2021 (Victoria lineage)-like virus

Cell culture-based and recombinant (ccIIV4 and RIV4) influenza vaccines contain HA derived from:

- influenza A/Wisconsin/67/2022 (H1N1) pdm09-like virus
- influenza A/Massachusetts/18/2022 (H3N2)-like virus
- influenza B/Austria/1359417/2021 (Victoria lineage)-like virus

### Storage

All influenza vaccine should be stored at 36°–46°F (2°–8°C) and should not be frozen.<sup>1</sup> Multidose vials should not be used after the beyond-use date, after being accessed for the first dose.<sup>1</sup> Additional storage and handling guidelines are available on the vaccine package inserts.<sup>3</sup>

### Inactivated Influenza Vaccines (IIV)

The IIV vaccines available this season are:

- Egg-based (IIV3): Afluria® MDV, Fluarix®, FluLaval®, and Fluzone® are licensed for persons aged ≥6 months.<sup>3</sup>
- Cell culture-based (ccIIV3): Flucelvax® is licensed for persons aged ≥6 months.<sup>3</sup>
- Egg-based high dose (HD-IIV3): Fluzone High-Dose® is licensed for persons aged ≥65 years.<sup>3</sup>
- Egg-based with MF59 adjuvant (aIIV3): Fluad® is licensed for persons aged ≥65 years.<sup>3</sup>

### Recombinant Influenza Vaccine (RIV)

Flublok® (RIV3) contains recombinant HA produced in an insect cell line using genetic sequences from cell-derived influenza viruses. Flublok® (RIV3) may be used in persons aged ≥18 years.<sup>3</sup>

### Live-Attenuated Influenza Vaccine (LAIV)

FluMist® (LAIV3) contains live, attenuated viruses that only replicate efficiently at temperatures present in the nasal mucosa. If the recipient sneezes immediately after administration, the dose should not be repeated.<sup>1</sup> FluMist® (LAIV3) is available for persons aged 2 through 49 years who are not pregnant.<sup>1</sup>

### References

1. CDC. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the ACIP—United States, 2024–25 Influenza Season. *MMWR* 2024;73(5);1-25. Available at: [https://www.cdc.gov/mmwr/volumes/73/rr/rr7305a1.htm?s\\_cid=rr7305a1\\_w](https://www.cdc.gov/mmwr/volumes/73/rr/rr7305a1.htm?s_cid=rr7305a1_w)
2. Alaska Epidemiology *Bulletin*. “Influenza Vaccine Recommendations and Administration for the 2024–25 Season”. No. 8, September 10, 2024. Available at: [https://epi.alaska.gov/bulletins/docs/b2024\\_08.pdf](https://epi.alaska.gov/bulletins/docs/b2024_08.pdf)
3. U.S. Food and Drug Administration, Vaccines, Blood, and Biologics: Manufacturer Package Inserts. Available at: <https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states>

**Table. Alaska Immunization Program-Supplied Influenza Vaccines**

Trade Name	Manufacturer	Presentation	Age Indication	HA (IIVs/ RIV3) or virus count (VAIV3) per dose	Route	Mercury (from thimerosal)
<b>Standard dose, egg based (IIV3)</b>						
Afluria®	Seqirus	5.0 mL MDV	6–35 months ≥3 years	7.5 µg/0.25 mL dose 15 µg/0.5 mL dose	IM	24.5 µg/0.5 mL
Fluzone®	Sanofi Pasteur	5.0 mL MDV*, 0.5 mL PFS	≥6 months	15 µg/0.5 mL dose	IM	25 µg/0.5 mL
<b>Standard dose, cell culture based (ccIIV3)</b>						
Flucelvax®	Seqirus	0.5 mL PFS	≥6 months	15 µg/0.5 mL dose	IM	--
<b>High dose, egg based (HD-IIV3)</b>						
Fluzone HD®	Sanofi Pasteur	0.5 mL PFS	≥65 years	60 µg/0.5 mL dose	IM	--
<b>Standard dose, egg-based vaccine with MF59 adjuvant (aIIV3)</b>						
Fluad®	Seqirus	0.5 mL PFS	≥65 years	15 µg/0.5 mL dose	IM	--
<b>Egg based (LAIV3)</b>						
FluMist®	AstraZeneca	0.2 mL PFIS	2–49 years	10 fluorescent focus units/0.2mL	NAS	--

**Abbreviations:** IIV = inactivated influenza vaccine; RIV = recombinant influenza vaccine; LAIV = live attenuated influenza vaccine; cc = prefix indicating cell culture-based vaccine; a = prefix indicating adjuvanted inactivated vaccine; numeric suffix = specifies number of HA antigens in the vaccine; IM = intramuscular; MDV = multi-dose vial; NAS = nasal; PFS = pre-filled syringe; PFIS = pre-filled intranasal spray

\*Fluzone® is currently approved for ages 6 through 35 months at either 0.25 mL or 0.5 mL per dose.